GSK gets European approval for bird flu vaccine
LONDON GlaxoSmithKline has received European approval for a vaccine that fights H5N1 virus, also called bird flu, according to Forbes.
The company expects a good chance of a pandemic occurring with the H5N1 virus, and although no signs point to a worldwide pandemic, the company wants to assure governments that it has the vaccine just in case.
Also, questions will now start to rise as to what happens if the next pandemic isn’t the H5N1 strain? The vaccine would most likely be useless against other strains.
But, a spokesperson for GlaxoSmithKline said that the company believed an eventual pandemic would involve a strain in the H5N1 family, and that a pre-pandemic treatment would save the four-to-six-month delay of having to react to an official pandemic announcement. “The U.K. government could buy it tomorrow and vaccinate us tomorrow,” she said.
In 2007, Finland, Switzerland and the United States all placed orders for GSK’s H5N1 vaccine totaling $285.1 million.
Scientific Labs shut down by the FDA
WASHINGTON The Food and Drug Administration announced that Scientific Laboratories and its president, Rajeshwari Patel, and chief executive officer, Amit Roy, have signed a Consent Decree of Permanent Injunction that bars the company from manufacturing and distributing drug products until they bring their manufacturing operations into compliance with law and obtain approval for their products.
Scientific Labs is a contract manufacturer and distributor of various prescription cough and cold products. The government’s complaint, filed by the U.S. Department of Justice, alleged violations of the Federal Food, Drug and Cosmetic Act. The company failed to seek required FDA approval for some of its products and failed to comply with current good manufacturing practice requirements.
The unapproved new drugs manufactured and marketed as prescription cough and cold products include: B-Vex Suspension, Ben-Tann Suspension, D-Tann Suspension, D-Tann AT Suspension, D-Tann CT Suspension, D-Tann DM Suspension, D-Tann HC Suspension, Dur-Tann DM Suspension, Duratan DM Suspension, L-All 12 Suspension, Nazarin Liquid, and Nazarin HC Liquid. Because these drugs have not undergone FDA review nor received approval, their safety and effectiveness have not been established. Additionally, the FDA has not reviewed the adequacy and accuracy of the directions and warnings in their labeling.
The FDA had warned Scientific Labs against violating the FD&C Act and about the risk of enforcement action if it failed to take corrective measures.
“The FDA will not allow a company to put the public’s health at risk,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “These unapproved new drugs have not undergone FDA review for safety and efficacy and may pose potential health risks.”
The consent decree bars the defendants from manufacturing and distributing any drug until they obtain required FDA approval and fully comply with CGMP requirements. The defendants must destroy their illegal drugs. The consent decree also allows the FDA to order the defendants to shut down in the event of future violations.
Amgen cancer drug trials show significantly reduced fracture risk
THOUSAND OAKS, Calif. Amgen’s cancer drug denosumab cuts fracture risk in cancer patients and women with postmenopausal osteoporosis, tests have shown.
According to early results released by the American Society of Clinical Oncology, the experimental cancer drug reduced fracture risk in 64 percent of the 111 patients tested, most of whom had breast and prostate tumors. Breast and prostate cancer are two types of cancer likely to spread to bones.
Results of Phase III testing of the drug released last month showed increases in bone mineral density among women with postmenopausal osteoporosis. Those tests examined 332 patients over a two-year period in which subjects received injections of denosumab twice a year.
Denosumab is a genetically engineered antibody that inhibits RANK Ligand, a protein that contributes to bone loss.